Business Standard

42 more cancer drugs under price control, profit margin cap at 30%

The NPPA has the right to cap prices of scheduled drugs, or use extraordinary powers in case of other drugs

Pharmaceuticals, drugs, pharma industry, medical, health, lab
Premium

Veena Mani New Delhi
The National Pharmaceutical Pricing Authority (NPPA) has said the profit margin of some anti-cancer drugs has been capped at 30 per cent. The authority has invoked the “extraordinary powers” it had used to cap prices of coronary stents, the NPPA said in a notification.

Under Para 19 of the Drug Price Control Order, 2019, the NPPA can slash prices of drugs that are not part of schedule 1.

Non-scheduled formulations of 42 drugs, which are used to treat cancer have been brought under the price cap. Previously, 57 anti-cancer drugs were under the price control. The trade margin cap would

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 27 2019 | 10:28 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com